

Information for Customers Regarding Injectables Supply

March 27, 2015 -- Mylan has an unwavering commitment to quality everywhere we operate. By way of example, in 2013, Mylan acquired the Agila injectables businesses from Strides Arcolab Limited to create a leading global injectables platform. Since the acquisition, we have been taking the steps necessary to integrate the Agila business into Mylan's One Quality Standard and ensure its position as a high quality, reliable source of injectables for the long term. We continue to make progress in implementing Mylan's One Quality Standard across the largest sites in the Agila manufacturing platform, specifically SFF and SPD, and we supply quality injectable products from those sites to customers around the world.

As part of this on-going process, Mylan has made the proactive decision to temporarily cease commercial production and distribution at certain smaller Agila sites -- Onco Therapies Limited (OTL), Beta Lactam Division (BLD), and Hosur -- while we continue integration, enhancement and remediation efforts there.

However, these actions are entirely consistent with our approach across all of our facilities and Agila is no different. While we may continue to have some issues as we implement our integration, enhancement and remediation efforts, we are confident that a deliberate, thorough approach to assure a sustainable culture of quality is the right way forward.

Although we are currently not producing or supplying product from the impacted sites, we intend to resume full commercial activities and supply from these sites as soon as possible. Mylan is in close contact with FDA as we work to resume supply.

Several marketed and pipeline products on FDA drug shortage lists are manufactured at OTL and Hosur. Some of these are qualified and can be moved to another site. Mylan has advised FDA of the impacted products so that Mylan and the Agency can coordinate to take appropriate actions to mitigate shortages.